Status:

TERMINATED

Thyroid Function of Pediatric Subjects Following Isovue® Administration

Lead Sponsor:

Bracco Diagnostics, Inc

Conditions:

Hypothyroidism

Eligibility:

All Genders

Up to 3 years

Phase:

PHASE4

Brief Summary

This is a Phase IV prospective, multicenter, observational study to estimate the proportion of subjects 0 to 3 years of age who develop abnormal thyroid function after exposure to intravascular admini...

Eligibility Criteria

Inclusion

  • Is male or female from 0 to 3 years of age;
  • Is scheduled to undergo a radiologic examination that requires intravascular administration of ISOVUE as part of his/her standard of care;
  • Has normal baseline thyroid function tests (TSH, total T3, total T4, and fT4) performed at a local laboratory with blood sample obtained within one week prior to ISOVUE administration;
  • Written informed consent is obtained from the subject's parent(s) or legally acceptable representative(s) (according to local regulations) who are willing to comply with the protocol requirements.

Exclusion

  • Has any known allergy to one or more of the ingredients of ISOVUE;
  • Has been diagnosed with congenital hypothyroidism;
  • Has undergone radiation treatments to the head or neck;
  • Is currently on thyroid replacement therapy;
  • Is on therapy with dopamine or any treatment which may affect the thyroid function testing results;
  • Has been exposed to any topical iodinated product within 30 days prior to enrollment in the present study;
  • Has been exposed to an iodinated contrast agent within 1 year prior to enrollment in the present study, including any administration of iodinated contrast agents during placement of a central line;
  • Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.

Key Trial Info

Start Date :

March 26 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 25 2022

Estimated Enrollment :

17 Patients enrolled

Trial Details

Trial ID

NCT03779906

Start Date

March 26 2019

End Date

March 25 2022

Last Update

July 30 2025

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Phoenix Children's Hospital

Phoenix, Arizona, United States, 85016

2

Children's Hospital and Medical Center

Omaha, Nebraska, United States, 68114

3

Children's Hospital Medical Center of Akron

Akron, Ohio, United States, 44308

4

Medical University of South Carolina (MUSC)

Charleston, South Carolina, United States, 29425